Learn more about Peter Attia’s digital program
Silencing the alarm over a recent paper on dietary protein and atherosclerosis
A recent report that high protein intake contributes to atherosclerosis has limited relevance to anyone but transgenic mice
#289 – AMA #56: Cancer screening: pros and cons, screening options, interpreting results, and more
“There has been a pretty clear and consistent benefit [to cancer screening] that has been demonstrated, and the exceptions I think have a pretty clear sense of why.” —Peter Attia
Do GLP-1 receptor agonists improve cardiovascular health independently of weight loss?
A new trial has reported that the GLP-1 receptor agonist semaglutide reduces risk of cardiovascular events in patients with obesity – but that’s not the question we ought to be asking.
#258 – AMA #48: Blood pressure—how to measure, manage, and treat high blood pressure
“If you care about your brain, if you care about your heart and if you care about your kidneys, you need low blood pressure. I think we can say that as confidently as we can say almost anything in medicine.” —Peter Attia
#255 ‒ Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease and CVD, familial hypercholesterolemia, and more | John Kastelein, M.D., Ph.D.
“One of the things that is so dangerous about this disorder is that the plaque that you get in FH is a soft plaque.” —John Kastelein
#252 ‒ Latest insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting | Rhonda Patrick, Ph.D.
“My perspective has shifted as any scientist that’s following data should… When new data comes out, you have to reassess things.” —Rhonda Patrick
#247 ‒ Preventing cardiovascular disease: the latest in diagnostic imaging, blood pressure, metabolic health, and more | Ethan Weiss, M.D.
“If everybody got truly optimal medical therapy, if we didn’t have barriers to using all these tools in everybody, I think this disease would largely be controlled.” —Ethan Weiss
#238 – AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease
“ApoB is a necessary, though not sufficient, factor in the development of ASCVD which means the more you lower it, the more you lower risk. Full stop.” —Peter Attia
#230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more | Erin Michos, M.D.
“How we live the first half of our lives really influences our freedom for morbidity and mortality the second half of our lives.” —Erin Michos
#229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB
“Not everybody dies from atherosclerosis, but… everybody dies with it.” —Peter Attia